01 How it works
KPV appears to calm inflammation from inside cells by dialling down NF-κB, a master switch for inflammatory signals. In animal models of colitis it reduced gut inflammation, which is why it is mostly used for gut and skin conditions.
02 Common uses
03 Run profile
Started low and stepped up over the first month, then held. Once a day, weekends off, usually in twelve-week blocks with a four-week break.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
04 Pairs well with
05 What to watch for
Mild redness or discomfort where you inject. Notably no tanning or appetite effects. Signs of infection, or a reaction that worsens after 48 hours, need checking.
06 Evidence & status
Not approvedPromising animal and cell research, especially for gut inflammation. There are no published human trials; what exists in people is real-world reports.
Not FDA-approved. Recommended 8–6 for the 503A compounding list by an FDA advisory panel in July 2026, a non-binding vote. On 28 October 2026 HHS issued an interim enforcement-discretion policy that lets state-licensed pharmacies and physicians compound single-ingredient KPV, and only as a topical or oral product, not injected while FDA rulemaking continues. It is still not on the 503A list, and there is no final FDA decision.
Sources
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationGastroenterology, 2008 · Reference
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseaseInflammatory Bowel Diseases, 2008 · Reference
- alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugsAnnals of the Rheumatic Diseases, 2007 · Review
- Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseasesEndocrine Reviews, 2008 · Review
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration, 2026 · Regulator document
- HHS Draft Policy Eases Enforcement on 6 Compounded PeptidesThe American Journal of Managed Care (AJMC), 2026 · Regulator document
- The Prohibited ListWorld Anti-Doping Agency, 2026 · Regulator document
Status and sources last checked November 3, 2026. Something out of date? Tell us.
07 How long until it works
There are no human trials of KPV, so there is no measured timescale in people. In the animal colitis models on this page, inflammation markers fell over days to a couple of weeks of dosing; the gut absorbs KPV through the same transporter it uses for food peptides, which is the basis for the oral use people describe.
People using it for gut or skin flares report change within two to three weeks. The twelve-week block with a break is common use, and the break exists mainly because nothing is known about long-term dosing in people.
08 KPV vs BPC-157 for the gut
They are the two peptides people reach for with gut complaints, and they are thought to do different things. BPC-157 is a repair peptide: in animal work it brings blood supply and rebuilding cells to damaged tissue, gut lining included. KPV is an anti-inflammatory: a fragment of alpha-MSH that turns down NF-κB, the master switch for inflammatory signalling, inside cells.
Neither has a human trial for gut conditions. The usual framing is BPC-157 for irritation and damage, KPV for inflammation that keeps flaring, and the two together when both seem to be going on; the KLOW Stack on this site includes both. That framing is common use, not evidence.
The BPC-157 dossier →09 Stacking
BPC-157 is the usual partner, and KPV is the “K” in the KLOW Stack alongside GHK-Cu, BPC-157 and TB-500. No study has tested any of these combinations. A combined vial is outside the October 2026 HHS compounding policy, which covers single-ingredient products only.
10 Where it stands legally
KPV is not approved anywhere. In July 2026 the FDA’s advisory committee voted 8–6 to recommend it for the 503A compounding list, against FDA reviewers’ advice. On 28 October 2026 HHS issued an interim policy under which it will not take enforcement action against licensed pharmacies and physicians compounding single-ingredient KPV, but only as a topical or oral product. Injected KPV, which is how this site’s schedule is written, is outside the policy.
In sport, a substance with no regulatory approval falls under S0 of WADA’s Prohibited List, so KPV is banned at all times for tested athletes.
11 FAQ
Will it tan me like Melanotan?
No — KPV is only the anti-inflammatory end of alpha-MSH and does not affect pigment.
Can it be taken orally?
Oral forms are used for the gut. Ask about the differences before choosing.
Why cycle it?
The usual pattern is twelve weeks on, four off — a conservative default for most compounds without long-term data.
Is KPV better taken orally?
For gut use, oral KPV is the route the animal work points to and the route the HHS policy covers. There is no human comparison. For skin and general use, injection is what people describe.
Is injected KPV covered by the HHS policy?
No. The October 2026 policy covers topical and oral KPV only.
Is KPV banned in sport?
Yes, under WADA’s S0 category for non-approved substances.
Has KPV been tested in people?
No published human trial exists. The evidence is animal and cell work plus real-world reports.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.